In vivo gene therapy with interleukin-12 inhibits primary vascular tumor growth and induces apoptosis in a mouse model

被引:27
作者
Wang, C
Quevedo, ME
Lannutti, BJ
Gordon, KB
Guo, DQ
Sun, W
Paller, AS
机构
[1] Northwestern Univ, Sch Med, Dept Pediat, Chicago, IL 60611 USA
[2] Northwestern Univ, Sch Med, Dept Dermatol, Chicago, IL 60611 USA
关键词
anti-neoplastic agents; gene therapy; hemangioendothelioma; hemangioma; interleukin-12;
D O I
10.1046/j.1523-1747.1999.00587.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Interleukin-12 is proposed to have anti-neoplastic activity on the basis of both its anti-angiogenic and immunologic effects. Gene gun therapy with interleukin-12 cDNA into the peritumoral area of immunocompetent 129/J mice with life-threatening primary vascular tumors reduced tumor volume 7.5-fold and almost tripled the duration of mouse survival, in contrast with luciferase-bombarded control mice. Epidermal expression of mouse interleukin-12 elevated tumoral and serum levels of interferon-gamma and tumor necrosis factor-alpha, increased the tumoral populations of T lymphocyte and natural killer cells, and induced tumor apoptosis. Gene transfer of interleukin-12 had little effect on tumor volumes and survival of tumor-bearing athymic nude mice, emphasizing the requirement for T cell directed cellular immunity. Peritumoral gene gun introduction of interleukin-la may be a novel, cost-effective approach to limit the growth and associated mortality of life-threatening tumors.
引用
收藏
页码:775 / 781
页数:7
相关论文
共 25 条
[1]  
BRASIER AR, 1994, CURRENT PROTOCOLS MO
[2]  
Briscoe DM, 1997, J IMMUNOL, V159, P3247
[3]   ROLE OF INTERFERON-GAMMA IN MEDIATING THE ANTITUMOR EFFICACY OF INTERLEUKIN-12 [J].
BRUNDA, MJ ;
LUISTRO, L ;
HENDRZAK, JA ;
FOUNTOULAKIS, M ;
GAROTTA, G ;
GATELY, MK .
JOURNAL OF IMMUNOTHERAPY, 1995, 17 (02) :71-77
[4]   ANTITUMOR AND ANTIMETASTATIC ACTIVITY OF INTERLEUKIN-12 AGAINST MURINE TUMORS [J].
BRUNDA, MJ ;
LUISTRO, L ;
WARRIER, RR ;
WRIGHT, RB ;
HUBBARD, BR ;
MURPHY, M ;
WOLF, SF ;
GATELY, MK .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (04) :1223-1230
[5]   Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12 [J].
Cavallo, F ;
Signorelli, P ;
Giovarelli, M ;
Musiani, P ;
Modesti, A ;
Brunda, MJ ;
Colombo, MP ;
Forni, G .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (14) :1049-1058
[6]   INVIVO PROMOTER ACTIVITY AND TRANSGENE EXPRESSION IN MAMMALIAN SOMATIC TISSUES EVALUATED BY USING PARTICLE BOMBARDMENT [J].
CHENG, L ;
ZIEGELHOFFER, PR ;
YANG, NS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (10) :4455-4459
[7]  
Colombo MP, 1996, CANCER RES, V56, P2531
[8]  
Enjolras O, 1997, Adv Dermatol, V13, P375
[9]   Infants with Kasabach-Merritt syndrome do not have ''true'' hemangiomas [J].
Enjolras, O ;
Wassef, M ;
Mazoyer, E ;
Frieden, IJ ;
Rieu, PN ;
Drouet, L ;
Taieb, A ;
Stalder, JF ;
Escande, JP .
JOURNAL OF PEDIATRICS, 1997, 130 (04) :631-640
[10]  
HENDRZAK JA, 1995, LAB INVEST, V72, P619